Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent... Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.
- Mechanism
- Curator reviewed
Inhibition of HDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in an open chromatin structure and transcriptional activation. In vitro, SB939 causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of SB939 has not been fully characterized.
- Primary indication
- For the treatment of various forms of cancer.Curator reviewed
- Formula / weight
- C20H30N4O2 · 358.486 g/mol (avg)
- Code names
- SB-939
Resolves to
JHDKZFFAIZKUCU-ZRDIBKRKSA-NSMILESCCCCC1=NC2=C(C=CC(\C=C\C(=O)NO)=C2)N1CCN(CC)CCWhat you can answer from here — as of August 30, 2026
Which drugs share a target with Pracinostat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account